Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Drug Name Comment Schedule Date
NabumetonePDL I DEC / 13
Nadolol or its saltsPDL I DEC / 13
Nadroparin or its saltsPDL I DEC / 13
Nafarelin or its salts or derivativesPDL

Including but not limited to Nafarelin acetate.

I DEC / 13
Nafcillin or its salts or derivativesPDL

For veterinary use

I DEC / 13
Nalbuphine and any salt thereofC I JUN / 02
Nalidixic acidPDL I DEC / 13
Nalmefene or its saltsPDL I DEC / 13
Naloxegol or its saltsPDL

including but not limited to naloxegol oxalate

I JUN / 15
Naloxone hydrochloride injection,

when indicated for emergency use for opioid overdose

Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.

II FEB / 17
Naloxone hydrochloride nasal spray,

when indicated for emergency use for opioid overdose

Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.

II FEB / 17
Naloxone or its saltsPDL

including, but not limited to naloxone hydrochloride, except when indicated for emergency use for opioid overdose

I FEB / 17
Naltrexone or its salts PDL I DEC / 13
Naphazoline and its salts in nasal preparations for pediatric use II SEP / 98
Naphazoline and its salts. in nasal preparations for adult use and in ophthalmic products U
Naproxen or its salts

Except in preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base).

[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]

I MAR / 15
Naproxen or its salts..

In preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit, when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes exceeding the equivalent of 6,000 mg of naproxen base.

[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]

III MAR / 15
Naproxen or its salts..

In preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit, when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes of the equivalent of 6,000 mg of naproxen base or less.

[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]

U MAR / 15
Naratriptan or its saltsPDL I DEC / 13
NatalizumabPDL I DEC / 13
Nateglinide or its salts or derivativesPDL I DEC / 13
Nebivolol or its salts or derivativesPDL I DEC / 13
NecitumumabPDL I APR / 17
Nedocromil or its saltsPDL I DEC / 13
Nefazodone or its saltsPDL I DEC / 13
NelarabinePDL I DEC / 13
Nelfinavir or its saltsPDL I DEC / 13
Neocinchophen or its saltsPDL I DEC / 13
Neomycin or its salts or derivativesPDL

Including but not limited to: Paromomycin sulfate (for veterinary use)

I DEC / 18
Neostigmine saltsPDL I DEC / 13
NepafenacPDL I DEC / 13
Neratinib or its salts PDL I OCT / 19
Nesiritide or its saltsPDL I DEC / 13
NetupitantPDL I DEC / 17
Nevirapine or its saltsPDL I DEC / 13
Niacin (nicotinic acid)

in extended-release formulations, except when sold in a modified-release oral dosage form that provides 500 milligrams or more per dosage unit or per daily dose

II MAR / 10
Nialamide or its saltsPDL I DEC / 13
NicarbazinPDL

For human use

I DEC / 13
Nicardipine or its saltsPDL I DEC / 13
Nicotine or its saltsPDL

For human use - EXCEPT: (a) in natural substances; (b) in the form of a chewing gum containing 4 mg or less of nicotine per dosage unit; (c) in the form of a transdermal patch with a delivery rate of 22 mg or less of nicotine per day; (d) in a form to be administered into the oral cavity by means of a non-active device (one that operates on energy generated by the human body or by gravity) that delivers 4 mg or less of nicotine per dose for buccal absorption; or (e) in the form of a lozenge containing 4 mg or less of nicotine per dosage unit).

I AUG / 18
Nicotine or its saltsPDL

For veterinary use.

I DEC / 13
Nicotinic acidPDL

For human use - when sold in: (a) a modified-release oral dosage form that provides 500 milligrams or more per dosage unit or per daily dose; or (b) an immediate-release oral dosage form that provides more than 500 milligrams per dosage unit or per daily dose.

I DEC / 13
Nicotinyl-tartrate I SEP / 98
NifedipinePDL I DEC / 13
Nikethamide I SEP / 98
Nilotinib or its saltsPDL I DEC / 13
NilutamidePDL I DEC / 13
Nimodipine or its saltsPDL I DEC / 13
Nintedanib or its saltsPDL I AUG / 15
Niraparib or its salts PDL I OCT / 19
NitisinonePDL I NOV / 16
Nitric oxidePDL I DEC / 13
Nitrofurantoin or its saltsPDL

For human use.

I DEC / 13
Nitroglycerin

Except for sublingual immediate release dosage forms.

I SEP / 98
Nitroglycerin. sublingual immediate release dosage forms II SEP / 98
NitroscanatePDL I DEC / 13
NivolumabPDL I JAN / 16
Nizatidine and its saltsNR

When sold in an oral dosage form containing not more than the equivalent of 75 mg of nizatidine.*

I SEP / 98
Nizatidine or its saltsPDL

Except when sold in an oral dosage form containing not more than the equivalent of 75 mg of nizatidine.

I DEC / 13
Nomifensine or its saltsPDL I DEC / 13
Non-live recombinant herpes zoster vaccine

*Note that this listing does not apply to live herpes zoster vaccines as they have not been specifically reviewed by the NDSAC. Therefore, live herpes zoster vaccines would follow the general vaccine listings.

II JUL / 21
Norepinephrine and its salts levarterenol, noradrenaline II SEP / 98
NorfloxacinPDL I DEC / 13
Nortriptyline or its saltsPDL I DEC / 13
Novobiocin or its salts or derivativesPDL

For human use.

I DEC / 13
NusinersenPDL I AUG / 17
Nylidrin or its saltsPDL I DEC / 13
Nystatin and its salts and derivatives. in topical preparations for use on the skin III SEP / 98
Nystatin or its salts or derivativesPDL

For human use - except preparations for topical use on the skin.

I DEC / 13

69 result(s)


Footnotes

  • C - Drug is listed in the Schedule to Part G of the Food and Drug Regulations under the Controlled Drugs and Substances Act
    N - Drug is listed in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
    NR - Drug has not been reviewed by the NDSAC
    PDL - Drug is listed in the Health Canada Prescription Drug List
    TS - Drug is listed in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
    CR - Drug has been recommended for addition to the Controlled Drugs and Substances Act